Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

NCT05512390 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05512390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 26, 2023
Completion date
February 28, 2027
Enrollment
39 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse large b-cell lymphoma, follicular lymphoma